188
PHILADELPHIA — Spark Therapeutics, a locally based firm that devises and delivers gene therapy solutions, will open a 500,000-square-foot life sciences facility in Philadelphia’s University City neighborhood, a project that represents a $575 million capital investment. The facility will be part of a 1 million-square-foot campus at the intersection of 30th and Chestnut streets. Spark Therapeutics has entered into a 99-year ground lease with Drexel University to develop the project. Construction is scheduled to begin in the fourth quarter of 2022.